ALDX - Aldeyra says FDA may not approve dry eye drug stock plunges 63%
2023-10-16 10:54:01 ET
More on Aldeyra Therapeutics
- Aldeyra:Upcoming PDUFA, Strong NDA, Long Pipeline, Decent Cash
- Eyeing Returns: Aldeyra's Shift From Lab To Market
- Seeking Alpha’s Quant Rating on Aldeyra Therapeutics
- Historical earnings data for Aldeyra Therapeutics
- Financial information for Aldeyra Therapeutics
For further details see:
Aldeyra says FDA may not approve dry eye drug, stock plunges 63%